The antinociceptive effects of centrally administered CDP-choline on acute pain models in rats: The involvement of cholinergic system

Brain Research

Volumn 1117, Issue 1, 2006, Pages 92-100

  Hamurtekin, Emre ^a   Sibel Gurun, M ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

7 nicotinic receptor; Antinociception; CDP choline; Choline; Cholinergic; Cytidine

Indexed keywords

CITICOLINE; HEMICHOLINIUM 3; MECAMYLAMINE; METHYLLYCACONITINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; MALE; MOTOR PERFORMANCE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; WITHDRAWAL REFLEX; WRITHING TEST;

ACETYLCHOLINE; ACUTE DISEASE; ANALGESICS; ANIMALS; BRAIN; CHOLINERGIC FIBERS; CYTIDINE DIPHOSPHATE CHOLINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; INJECTIONS, INTRAVENTRICULAR; MALE; NEUROTRANSMITTER UPTAKE INHIBITORS; NICOTINIC ANTAGONISTS; NOCICEPTORS; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; SYNAPTIC TRANSMISSION;

ANIMALIA;

EID: 33750002031     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.07.118     Document Type: Article

References (58)

1. Adibhatla R.M., and Hatcher J.F. Cytidine 5′-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem. Res. 30 (2005) 15-23
2. Alkondon M., and Albuquerque E.X. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons: I. Pharmacological and functional evidence for distinct structural subtypes. J. Pharmacol. Exp. Ther. 265 (1993) 1455-1473
3. Alkondon M., Pereira E.F.R., Cortes W.S., Maelicke A., and Albuquerque E.X. Choline is a selective agonist of α7 nicotinic acetylcholine receptors in rat brain neurons. Eur. J. Neurosci. 9 (1997) 2734-2742
4. Alkondon M., Pereira E.F.R., and Albuquerque E.X. α-Bungarotoxin- and methyllycaconitine-sensitive nicotinic receptors mediate fast synaptic transmission in interneurons of rat hippocampal slices. Brain Res. 810 (1998) 257-263
5. Amenta F., Parnetti L., Gallai V., and Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?. Mech. Ageing Dev. 16 (2001) 2025-2040
6. Arslan B.Y., Ulus I.H., Savci V., and Kiran B.K. Effects of intracerebroventricular injected choline on cardiovascular functions and sympathoadrenal activity. J. Cardiovasc. Pharmacol. 17 (1991) 814-821
7. Bars D., Gozariu M., and Cadden S.W. Acute pain measurements in animals; part I. Ann. Fr. Anesth. Reanim. 20 (2001) 347-365
8. Bartolini A., Ghelardini C., Fantetti L., Malcangio M., Malmberg-Aiello P., and Giotti A. Role of muscarinic receptor subtypes in central antinociception. Br. J: Pharmacol. 105 (1992) 77-82
9. Blusztajn J.K., and Wurtman R.J. Choline and cholinergic neurons. Science 221 (1983) 614-620
10. Cacabelos R., Alvarez X.A., Franco-Maside A., Fernandez-Novoa L., and Caamano J. Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multiinfarct dementia. Ann. NY. Acad. Sci. 695 (1993) 321-323
11. Cacabelos R., Alvarez X.A., Fernandez-Novoa L., and Lombardi V.R. A pharmacogenomic approach to Alzheimer's disease. Acta Neurol. Scand., Suppl. 176 (2000) 12-19
12. Cavun S., and Savci V. CDP-choline increases plasma ACTH and potentiates the stimulated release of GH, TSH and LH: the cholinergic involvement. Fundam. Clin. Pharmacol. 18 (2004) 513-523
13. Cavun S., Savci V., and Ulus I.H. Centrally injected CDP-choline increases plasma vasopressin levels by central cholinergic activation. Fundam. Clin. Pharmacol. 18 (2004) 71-77
14. Cohen E.L., and Wurtman R.J. Brain acetylcholine: increase after systemic choline administration. Life Sci. 16 (1975) 1095-1102
15. Damaj M.I., Fei{dotless}-Yi{dotless}n M., Glassco W., Glennon R.A., and Martin B.R. Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J. Pharmacol. Exp. Ther. 284 (1998) 1058-1065
16. Damaj M.I., Meyer E.M., and Martin B.R. The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. Neuropharmacology 39 (2000) 2785-2791
17. Decker M.W., Rueter L.E., and Bitner R.S. Nicotinic acetylcholine receptor agonists: a potential new class of analgesics. Curr. Top. Med. Chem. 4 (2004) 369-384
18. Dixon C.E., Ma X., and Marion D.W. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J. Neurotrauma 14 (1997) 161-169
19. D'Orlando K.J., and Sandage Jr. B.W. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurol. Res. 17 (1995) 281-284
20. Drasdo A., Caufield M., Bertrand D., Bertrand S., and Wonnacott S. Methyllycaconitine: a novel nicotinic antagonist. Mol. Cell. Neurosci. 3 (1999) 237-243
21. Flores C.M. The promise and pitfalls of a nicotinic cholinergic approach to pain management. Pain 88 (2000) 1-6
22. Ghelardini C., Galeotti N., Calvani M., Mosconi L., Nicolai R., and Bartolini A. Acetyl-l-carnitine induces muscarinic antinociception in mice and rats. Neuropharmacology 43 (2002) 1180-1187
23. Gillberg P., and Aquilonius S. Cholinergic, opioid and glycine receptor binding sites localized in human spinal cord by in vitro autoradiography. Changes in amyotrophic lateral sclerosis. Acta Neurol. Scand. 72 (1985) 299-306
24. Gurun M.S., Leinbach R., Moore L., Lee C.S., Owen M.D., and Eisenach J.C. Studies on safety of paraben-containing neostigmine for intrathecal administration. Anest. Analg. 85 (1997) 317-323
25. Gurun M.S., Savci V., and Ulus I.H. Intracerebroventricular choline reverses hypotension induced by acute chemical sympathectomy. J. Auton. Pharmacol. 17 (1997) 153-155
26. Hargreaves K., Dubner R., Brown F., Flores C., and Jaris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32 (1988) 77-88
27. Hendershot L.C., and Forsaith J. Antagonism of the frequency of phenylquinone-induced writhing in the mouse by weak analgesics and nonanalgesics. J. Pharmacol. Exp. Ther. 125 (1959) 237-240
28. Ireson J.D. A comparison of the antinociceptive actions of cholinomimetic and morphine-like drugs. Br. J. Pharmacol. 40 (1970) 92-101
29. Kennedy C. P2X receptors: targets for novel analgesics?. Neuroscientist 11 (2005) 345-356
30. Khan I., Yaksh T.L., and Taylor P. Ligand specificity of nicotinic acetylcholine receptors in rat spinal cord: Studies with nicotine and cytisine. J. Pharmacol. Exp. Ther. 270 (1994) 159-166
31. Koshimura K., Miwa S., Lee K., Hayashi Y., Hasegawa H., Hamahata K., Fujiwara M., Kimura M., and Itokawa Y. Effects of choline administration on in vivo release and biyosynthesis of acetylcholine in the rat striatum as studied by in vivo microdialysis. J. Neurochem. 54 (1990) 533-539
32. Liu X.J., and Salter M.W. Purines and pain mechanisms: recent developments. Curr. Opin. Develop. Drugs 6 (2005) 65-75
33. Lloyd G.K., and Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J. Pharmacol. Exp. Ther. 292 (2000) 461-467
34. Lopez G.-Coviella I., Agut J., Von Borstel R., and Wurtman R.J. Metabolism of cytidine (5′)-diphosphocholine (CDP-choline) following oral and intravenous administration to the human and the rat. Neurochem. Int. 11 (1987) 293-297
35. Lopez G.-Coviella I., Agut J., Savci V., Ortiz J.A., and Wurtman R.J. Evidence that 5′-cytidinediphosphocholine can affect brain composition by increasing choline and cytidine plasma levels. J. Neurochem. 65 (1995) 889-894
36. Marks M.J., Pauly J.R., Gross S.D., Deneris E.S., Hermans-Borgmeyer I., Heinemann S.F., and Collins A.C. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J. Neurosci. 12 (1992) 2765-2784
37. Mike A., Castro N.G., and Albuquerque E.X. Choline and acetylcholine have similar kinetic properties of activation and desensitization on the α7 nicotinic receptors in rat hippocampal neurons. Brain Res. 882 (2000) 155-168
38. Papke R.L., Bencherif M., and Lippiello P. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the α7 subtype. Neurosci. Let. 213 (1996) 201-204
39. Pedigo N.W., Dewey W.L., and Harris L.S. Determination and characterization of the antinociceptive activity of intraventricularly administered acetylcholine in mice. J. Pharmacol. Exp. Ther. 193 (1975) 845-852
40. Randall L.O., and Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. 111 (1957) 409-419
41. Sargent P.B. The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16 (1993) 403-443
42. Savci V., and Wurtman R.J. Effect of cytidine on membrane phospholipid synthesis in rat striatal slices. J. Neurochem. 64 (1995) 378-384
43. Savci V., Cavun S., Goktalay G., and Ulus I.H. Cardiovascular effects of intracerebroventricularly injected CDP-choline in normotensive and hypotensive animals: the involvement of cholinergic system. Naunyn-Schmiedeberg's Arch. pharmacol. 365 (2002) 388-398
44. Savci V., Goktalay G., Cansev M., Cavun S., Yilmaz M.S., and Ulus I.H. Intravenously injected CDP-choline increases blood pressure and reverses hypotension in haemorrhagic shock: effect is mediated by central cholinergic activation. Eur. J. Pharmacol. 408 (2003) 129-139
45. Seguela P., Wadiche J., Dineleymiller K., Dani J.A., and Patrick J.W. Molecular cloning, functional properties, and distribution of rat brain-alpha7-a nicotinic cation channel highly permeable to calcium. J. Neurosci. 13 (1993) 596-604
46. Suryani L.K., Adnjana T.A.K., and Jensen G. Citicoline treatment of memory deficits in elderly people. Int. J. Geriatr. Psychiatry 3 (1988) 235-236
47. Ulus I.H., and Wurtman R.J. Choline administration: activation of tyrosine hydroxylase in dopaminergic neurons of rat brain. Science 194 (1976) 1060-1061
48. Ulus I.H., Wurtman R.J., Mauron C., and Blusztajn J.K. Choline increases acetylcholine release and protects against the stimulation induced decrease in phosphatide levels within membranes of rat corpus striatum. Brain Res. 484 (1989) 217-227
49. Wada E., Wada K., Boulter J., Deneris E., Heinemann S., Patrick J., and Swanson L. Distribution of alpha2, alpha3, alpha4, and beta2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J. Comp. Neurol. 284 (1989) 314-335
50. Wang Y., Su D.M., Wang R.H., Liu Y., and Wang H. Antinociceptive effects of choline against acute and inflammatory pain. Neuroscience 132 (2005) 49-56
51. Warach S., Pettigrew L.C., Dashe J.F., Pullicino P., Lefkowitz D.M., Sabounjan L., Harnett K., Schwiderski U., and Grammans R. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 investigators. Ann. Neurol. 48 (2000) 713-722
52. Weiss G.B. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci. 56 (1995) 637-660
53. William A., Carlezon Jr., Pliakis A.M., Parow A.M., Detke M.J., Cohen B.M., and Renshaw P.F. Antidepressant-like effects of cytidine in the forced swim test in rats. Biol. Psychiatry 51 (2002) 882-889
54. Wurtman R.J. Neuronal death mechanisms in cerebral ischemia: laboratory at the clinic. Rev. Neurol. 29 (1999) 524-526
55. Wurtman R.J., Regan M., Ulus I.H., and Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem. Pharmacol. 60 (2000) 989-992
56. Yaksh T.L., Dirksen R., and Harty G.J. Antinociceptive effect of intrathecally injected cholinomimetics drugs in the rat and cat. Eur. J. Pharmacol. 117 (1985) 81-88
57. Yaksh T.L., Grafe M.R., Malkmus S., Rathbun M.L., and Eisenach J.C. Studies on the safety of chronically administered intrathecal neostigmine methylsulfate in rats and dogs. Anesthesiology 82 (1995) 412-427
58. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110